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Abstract
Background: Use of synthetic cathinones, which are designer stimulants found in “bath salts,” has increased dramatically 
in recent years. Following governmental bans of methylenedioxypyrovalerone, mephedrone, and methylone, a second 
generation of synthetic cathinones with unknown abuse liability has emerged as replacements.
Methods: Using a discrete trials current intensity threshold intracranial self-stimulation procedure, the present study assessed 
the effects of 2 common second-generation synthetic cathinones, α‐pyrrolidinopentiophenone (0.1–5 mg/kg) and 4-methyl-
N-ethcathinone (1–100 mg/kg) on brain reward function. Methamphetamine (0.1–3 mg/kg) was also tested for comparison 
purposes.
Results: Results revealed both α‐pyrrolidinopentiophenone and 4-methyl-N-ethcathinone produced significant intracranial 
self-stimulation threshold reductions similar to that of methamphetamine. α‐Pyrrolidinopentiophenone (1 mg/kg) produced a 
significant maximal reduction in intracranial self-stimulation thresholds (~19%) most similar to maximal reductions produced 
by methamphetamine (1 mg/kg, ~20%). Maximal reductions in intracranial self-stimulation thresholds produced by 4-methyl-
N-ethcathinone were observed at 30 mg/kg (~15%) and were comparable with those observed with methamphetamine and α‐
pyrrolidinopentiophenone tested at the 0.3-mg/kg dose (~14%). Additional analysis of the ED50 values from log-transformed data 
revealed the rank order potency of these drugs as methamphetamine ≈ α‐pyrrolidinopentiophenone > 4-methyl-N-ethcathinone.
Conclusions: These data suggest that the newer second-generation synthetic cathinones activate the brain reward circuitry 
and thus may possess a similar degree of abuse potential as prototypical illicit psychostimulants such as methamphetamine 
as well as the first generation synthetic cathinone methylenedioxypyrovalerone, as previously reported.
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Introduction
For the first time in history, the number of unregulated novel 
psychoactive substances on international drug markets now 
exceeds those under international control (United Nations, 
2013). One of the most problematic classes of novel psychoac-
tive substances to emerge are synthetic cathinones, comprising 
approximately 18% of all unregulated substances in interna-
tional markets (United Nations, 2013). Synthetic cathinones first 
appeared in Europe in the mid 2000s and in the United States 
around 2009, and their use led to numerous reports of abuse, 
bizarre behavior, toxicity, and death (Prosser and Nelson, 2012; 
Rosenbaum et  al., 2012). The rise in popularity of synthetic 
cathinones is linked to their ease of procurement over the 
internet and in gas stations, smoke shops, and novelty stores 
(Spiller et al., 2011). Synthetic cathinones have been falsely mar-
keted as numerous products, the most recognizable being “bath 
salts,” and are typically labeled “not for human consumption” or 
“for research purposes only” to evade drug laws (United States 
Department of Justice, 2011c). Although many synthetic cathi-
none derivatives exist, 3,4-methylenedioxypyrovalerone (MDPV), 
mephedrone, or methylone, initially comprised approximately 
98% of all synthetic cathinones encountered in US drug seizures 
(United States Department of Justice, 2011a). Citing imminent 
threats to public health and safety, the US Drug Enforcement 
Administration (DEA) used their emergency scheduling author-
ity to temporarily classify these 3 drugs (now often referred to as 
first-generation bath salts) as Schedule I substances in October 
of 2011 (United States Department of Justice, 2011b). As of 2013, 
these first-generation synthetic cathinones are now perma-
nently classified as Schedule I substances in the United States 
(United States of America, 2012; United States Department of 
Justice, 2013a).
On January 22, 2013, the US DEA published a request for 
information specifically regarding 8 additional synthetic cathi-
nones, 2 of the most prominent being 4-methyl-N-ethcathinone 
(4-MEC) and α‐pyrrolidinopentiophenone (α-PVP) (DEA, 2013). 
Their similarity in chemical structure suggests that α-PVP and 
4-MEC likely emerged as replacements for MDPV and mephed-
rone, respectively (Figure 1).
Although literature regarding the neurochemistry, toxi-
cology, and abuse liability of first-generation synthetic cathi-
nones has emerged in recent years (Spiller et al., 2011; Coppola 
and Mondola, 2012; Baumann et al., 2013; Simmler et al., 2013; 
Watterson et al., 2013; Watterson and Olive, 2014), relatively little 
information exists regarding second-generation analogues such 
as α-PVP and 4-MEC (United States Department of Justice, 2013b). 
With regards to abuse liability, the potential for compulsive use 
(ie, addiction) of stimulant drugs generally increases as dopa-
mine (DA) to serotonin transporter (DAT/SERT) reuptake (IC50 
values) and/or release (EC50 values) ratios increase (ie, synaptic 
levels of DA are greater than 5-hydroxytrypamine, 5-HT). On the 
other hand, higher SERT to DAT ratios are generally associated 
with more entactogenic effects and episodic abuse patterns 
(Rothman and Baumann, 2003, 2006; Bauer et al., 2013a). Studies 
have revealed that α-PVP is a potent DA and norepinephrine 
transporter (DAT and NET, respectively) inhibitor, has relatively 
little affinity for the serotonin transporter (DAT/SERT IC50 > 781) 
(Meltzer et al., 2006; Marusich et al., 2014), increases extracellular 
DA release in the striatum (Kaizaki et al., 2014), and has locomo-
tor enhancing properties similar to MDPV (DAT/SERT IC50 ≈ 806–
816) and methamphetamine (DAT/SERT IC50 ≈ 10–25; DAT/SERT 
EC50 ≈ 152) (Rothman and Baumann, 2003; Baumann et al., 2012b; 
Kaizaki et al., 2014; Marusich et al., 2014). On the other hand, in 
vitro assays have shown that 4-MEC inhibits the reuptake of DAT, 
NET, and SERT with approximately equal affinity but also acts 
as a 5-HT releaser with a similar DAT to SERT ratio (DAT/SERT 
IC50 ≈ 1.85) (Iversen et al., 2013; Simmler et al., 2014) to methylone 
(DAT/SERT IC50 ≈ 2; DAT/SERT EC50 ≈ 1.82; Baumann et  al., 2012a) 
and 3,4-methylenedioxymethamphetamine (MDMA; DAT/SERT 
EC50 ≈ 0.97; Baumann et al., 2012a). To our knowledge, the effects 
of 4-MEC on locomotor activity have not been reported. It is also 
important to note here that DAT to SERT ratios differ slightly 
between laboratories and/or as a result of cell types used (eg, 
rat brain synaptosomes, HEK 293 cells expressing human trans-
porters, etc.). Thus, despite their somewhat unique in vitro pro-
files, these newer synthetic cathinones appear to exert effects 
on monoaminergic signaling and suggest that α-PVP will have 
stimulant effects and high compulsive abuse potential similar 
to methamphetamine (METH) and the first-generation synthetic 
cathinone MDPV (Aarde et  al., 2013; Watterson et  al., 2014). In 
contrast, 4-MEC is predicted to have entactogenic effects and 
relatively lower compulsive abuse potential (ie, episodic use) 
similar to MDMA and the first-generation synthetic cathinone 
methylone (Watterson et al., 2012).
 However, there are currently no published behavioral stud-
ies that have directly assessed the potential abuse liability of 
α-PVP and 4-MEC. Thus, the current study sought to determine 
the effects of α-PVP and 4-MEC, along with methamphetamine 
for comparison, on thresholds for intracranial self-stimulation 
(ICSS) using a discrete trials current threshold determination 
procedure (Markou and Koob, 1992). The discrete trials current 
threshold ICSS task is commonly employed to assess abuse lia-
bility, with reductions in ICSS thresholds representing facilita-
tion of brain reward functioning and increases in ICSS threshold 
representing anhedonic/depression-like effects and inhibition 




All procedures were conducted with the approval of the 
Institutional Animal Care and Use Committee at Arizona State 
University in accordance with the Guide for Care and Use 
of Laboratory Animals as adopted by the National Institutes 
of Health. Male Sprague-Dawley rats (n = 5 for α-PVP, n = 5 
for 4-MEC, and n = 4 for METH) were obtained from Harlan 
Laboratories (Livermore, CA) and weighed approximately 250 g 
on arrival. Rats were individually housed according to National 
Institutes of Health standards on a reversed 12-hour light-dark 
Figure  1. Chemical structures of the traditional psychostimulants metham-
phetamine (METH) and methylenedioxymethamphetamine (MDMA), first-gen-
eration synthetic cathinones methylenedioxypyrovalerone (MDPV) and methy-
lone, and second-generation synthetic cathinones α‐pyrrolidinopentiophenone 
(α-PVP) and 4-methyl-N-ethcathinone (4-MEC).
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cycle (lights off at 6:00 am) and given ad libitum access to food 
and water during all experimental procedures, except during 
behavioral testing. All behavioral testing occurred during the 
dark phase between 8:00 am and 6:00 pm.
Drugs
α-PVP and 4-MEC were both obtained through Internet websites 
(NicePriceResearchChems.biz and www.researchchemz.com, 
respectively). Ten mg samples of both drugs were analyzed by 
liquid chromatography-mass spectrometry for purity and chemi-
cal composition at the Research Triangle Institute (Durham, 
NC). Samples were dissolved in methanol and analyzed using 
a Waters Synapt HDMS (Milford, MA) quadrupole time-of-flight 
mass spectrometer interfaced to a Waters Acquity UPLC system. 
Data were acquired using a capillary voltage of 3 kV, source tem-
perature of 120°C, desolvation temperature of 450°C, sampling 
cone at 30 V, and extraction cone at 3 V. The mass spectrometer 
was externally calibrated from 50 to 700 Da using sodium formate 
solution, and mass shifts during acquisition were corrected using 
leucine enkephalin as a lockmass. Liquid chromatography was 
performed using a BEH C18 column (2.1 × 50 mm, 1.7-µm particles) 
held at 30°C. Sample identity was confirmed based on exact mass, 
retention time, and fragmentation match to a certified reference 
standard from Cerilliant (Round Rock, TX). Both samples were 
determined to have an apparent purity of >95%. For all behav-
ioral studies, α-PVP, 4-MEC, and METH (Sigma Aldrich, St. Louis, 
MO) were dissolved in 0.9% sterile saline and administered via 
the intraperitoneal route in a volume of 1 mL/kg.
ICSS Surgical Procedures
Rats were anesthetized with isoflurane (2% vol/vol) vaporized 
oxygen and unilaterally implanted (right and left hemispheres 
counterbalanced across rats) with a stainless steel bipolar elec-
trode (PlasticsOne, Roanoke, VA; 2-mm diameter, insulated 
except at the ventral tip) into the medial forebrain bundle (ante-
rior-posterior −0.05 mm; medial-lateral ± 1.7 mm, dorsal-ventral 
−8.3 mm from dura) and secured to the skull with skull screws 
and dental cement. Rats were given 7 days to recover from sur-
gery before commencement of ICSS procedures, during which 
they received daily injections of 2.5 mg/mL meloxicam (0.15 mL 
volume) to minimize postsurgical discomfort.
ICSS Apparatus
All ICSS testing was conducted in operant conditioning cham-
bers (ENV-007CT; Med Associates) housed in sound-attenuating 
cubicles equipped with an exhaust fan to mask external noise. 
Chambers were equipped with a house light and a nose-poke 
aperture containing a light-emitting diode (LED) stimulus light 
(ENV-114M; Med Associates). The nose-poke aperture was 2.5 cm 
in diameter, located 5 cm above a stainless steel grid floor, and 
contained an infrared detector placed 0.64 cm from the front 
edge of the panel for recording responses. Located outside the 
chambers was a dual programmable ICSS stimulator (PHM-
150B/2; Med Associates) interfaced to a computer to deliver 
electrical current to the electrode. Chambers were interfaced to 
a PC using Med-PC IV software that controlled all stimulation 
parameters, test functions, and data collection.
ICSS Testing Procedures
The discrete-trials current threshold ICSS procedures used in 
the present study were identical to those described in previous 
publications from our laboratory (Watterson et  al., 2012, 2013, 
2014; also see Markou and Koob, 1992; Vlachou and Markou, 
2011). During all ICSS testing procedures, stimulation availability 
was signaled by illumination of the LED stimulus light located 
within the nose-poke aperture. Training began by allowing rats 
to spontaneously acquire nose-poke responses on an FR1 sched-
ule of reinforcement, which delivered a 200-millisecond square-
wave cathodal pulse of 120 µA at 100 Hz. Rats were required to 
exert a minimum of 600 nose pokes in a 30-minute session for 
2 sessions to progress to discrete trials training. During discrete 
trials training, each trial began with a free stimulation of 120 µA 
followed by a 7.5-second period during which the LED light 
remained on until the rat emitted a response that would yield 
an identical stimulation. Following the initial trial, the LED light 
was turned off and an inter-trial interval (ITI) was initiated, dur-
ing which responses were recorded but yielded no stimulation. 
Progression through discrete trial training required rats to meet 
criterion (>60% of total [trial + ITI] responses were correct trial 
responses) at 4 ITI lengths (2, 5, 10, and 15 seconds). Once rats 
completed discrete trials training, discrete trial current thresh-
old determination procedures began. All discrete trials current 
threshold sessions began with a stimulus intensity of 120  µA 
and progressed through 4 cycles of ascending and descending 
blocks of trials. At a given current intensity, 5-trial blocks began 
with a free stimulation, followed by a 7.5-second interval during 
which rats could emit a nose-poke response to receive an identi-
cal stimulation. Following a single trial response, the LED stimu-
lus light was turned off, initiating an ITI period between 7.5 and 
15 seconds (mean 10 seconds) that separated trials. Responses 
during the ITI further lengthened the ITI by 12.5 seconds. When 
rats emitted an appropriate response on ≥3 of 5 trials, elec-
trical stimulation was decreased by 5  µA for the next 5-trial 
block. Stimulation intensities continued to descend until the 
rats responded ≤2 of 5 trials during a given trial block, at which 
point the current intensities reversed into ascending mode, with 
5-µA increases in current intensity for the subsequent blocks. 
Therefore, the discrete trial current threshold procedure deter-
mined the lowest amount of current intensity (threshold) for 
which a rat was willing to emit responses. For each session, raw 
threshold scores were calculated by averaging the midpoint of 
current intensities between positive (responses to ≥3 of 5 trials) 
or negative (responses to ≤2 of 5) trial blocks.
Prior to all drug and vehicle testing, rats received a minimum 
of 10 days of baseline threshold assessment and were required 
to meet stable baseline criteria. These criteria were determined 
by threshold means for the most recent 8 sessions as well as 
submeans for the first and last 4 of these sessions. The differ-
ence in submeans was divided by the overall mean, and thresh-
old stability was considered to be met if the resulting percentage 
was <5 (Sidman, 1960). Baseline testing continued throughout 
experimentation to monitor stability, and drug testing was 
stopped if animals no longer displayed stability across baseline 
scores. In all cases, loss of stability occurred as a result of either 
loosening or complete detachment of the electrode implant 
from the skull.
Drugs were administered 20 minutes prior to placement into 
ICSS procedures. Drug doses were given in a randomized block 
design such that rats received each dose once before begin-
ning another block of testing. At the beginning of the experi-
ment, all subjects were to receive 5 determinations of each dose; 
however, loss of electrode implant or baseline stability meant 
some subjects received less. Rats that were administered 4-MEC 
received 2 to 5 determinations at each dose, and all rats that 
were administered α-PVP received 1 to 4 determinations at each 
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dose. A 100-mg/kg dose for 4-MEC and 5-mg/kg dose for α-PVP 
were also administered, but only once and only for a subset of 
rats (N = 4 for α-PVP; N = 3 for 4-MEC) because of apparent aver-
sive effects as indicated by robust ICSS threshold elevations. 
Because only a subset of rats received these higher doses, ICSS 
threshold determinations were not included in the statistical 
analysis. Rats receiving METH received 2 to 3 determinations 
at each dose with the exception of the 3-mg/kg dose, which 
was only assessed once in rats, also because of ICSS threshold 
increases. However, because all rats received a 3-mg/kg determi-
nation, ICSS thresholds at this dose for METH were included in 
statistical analyses.
Statistical Analyses
All statistical analyses were conducted using SigmaPlot (Systat 
Software, Inc. San Jose, CA). A  significance criterion of P < .05 
was used for all analyses. For each rat, raw ICSS current inten-
sity thresholds (in µA) for all vehicle and drug sessions con-
ducted once drug administration began were converted to 
scores reflecting the percent change from the mean of baseline 
thresholds obtained after reaching stabilization. For each dose, 
including vehicle, scores reflect the average percent change 
from the baseline score, which immediately preceded its deter-
mination for each individual animal. In addition to dose means, 
corresponding 95% confidence intervals (Figure  2) were calcu-
lated, and significance (between individual doses and vehicle) 
occurred when the 95% confidence intervals between individual 
doses and vehicle did not overlap (Cardinal and Aitken, 2006).
To perform dose-effect comparisons across the different 
drugs tested, doses were log transformed for each animal and 
a linear slope (line of best fit) was calculated on group means 
for the descending portion of dose-effect curves starting with 
the lowest dose tested and ending with the dose producing the 
largest observed mean maximal reduction in ICSS thresholds. 
Linear slopes were then used to calculate ED50 values for each 
drug and animal. Maximal reductions for each animal, regard-
less of dose, were also calculated. Next, slopes for the log-
transformed drug doses on the linear portion of the descending 
slopes (ED50 values in mg/kg) and maximal ICSS threshold 
decreases for METH, α-PVP, and 4-MEC were compared by a 
1-way between-subjects analysis of variance with Bonferroni 
posthoc tests. Slope and ED50 values from previously published 
data (Watterson et al., 2012, 2014) were also calculated (Table 1) 
but were not compared statistically because of the possibility 
of cohort effects.
Results
For 4-MEC (Figure 2A), significant reductions in ICSS thresholds 
vs vehicle were seen in the 10- (M = −11.86) and 30- (M = −15.09) 
mg/kg dose groups. For α-PVP (Figure 2B), significant reductions 
vs vehicle were seen in the 0.3- (M = −13.79) and 1- (M= − 19.03) 
mg/kg doses. For METH (Figure  2C), significant reductions vs 
vehicle were seen in the 0.3- (M = −13.40) and 1- (M = −19.82) mg/
kg doses.
For α-PVP, 4-MEC, and METH, higher doses (5, 100, and 3 mg/
kg, respectively) produced elevations in ICSS threshold values, 
with only METH producing significant elevations (mean ± 95% CI; 
α-PVP, 19.83 ± 38.64; 4-MEC, 28.00 ± 31.72; METH, 84.39 ± 69.48%).
The slope, ED50, and maximal effect values are shown in 
Table 1. There were no significant differences in slopes of the 
linear portions of the dose-response curves between the 3 drugs 
(F[2,11] = 1.63, P > .05). For ED50 values, a significant effect of 
drug was observed (F[2,11] = 46.05, P < .001), and posthoc analy-
ses revealed significant differences between METH and 4-MEC, 
METH and α-PVP, and α-PVP and 4-MEC (all Ps < .001). For com-
parison purposes, slope and ED50 values for MDPV and meth-
ylone were also calculated from previously published data 
(Watterson et al., 2012, 2014) but were not compared statistically. 
Finally, there were no significant differences observed in maxi-
mal reductions in ICSS thresholds (F[2,11] = 1.64, P > .05).
Discussion
To our knowledge, there are currently no published studies 
directly assessing the potential abuse liability of the second-
generation synthetic cathinones α-PVP or 4-MEC. The present 
study revealed that, similar to methamphetamine in the pre-
sent study and to MDPV and methylone in previous studies 
(Watterson et  al., 2012, 2014; Bonano et  al., 2013), both α-PVP 
and 4-MEC dose-dependently decreased ICSS thresholds in 
a discrete trials current threshold procedure. ICSS threshold 
reductions are commonly accepted as indicative of facilitated 
brain reward function and the interoceptive rewarding effects 
of drugs of abuse and thus provide evidence of abuse potential 
Figure 2. Effects of the second-generation synthetic cathinone (A) 4-methyl-N-ethcathinone (4-MEC) (1, 3, 10, 30, mg/kg), (B) α‐pyrrolidinopentiophenone (α-PVP) (0.1, 
0.3, 1, and 3 mg/kg), and the traditional psychostimulant (C) methamphetamine (METH) (0.1, 0.3, 1, and 3 mg/kg) on intracranial self-stimulation (ICSS) thresholds. Data 
represent mean ± 95% confidence interval and are expressed as a percent change in ICSS thresholds relative to the previous baseline session. N = 5, 5, and 4 in A, B, and 
C, respectively. *Symbols represent P < .05 vs. saline. In C, the confidence interval upper limit (no shown) for the 3-mg/kg dose = 153.87.
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in humans (Vlachou and Markou, 2011). At the highest doses 
tested, α-PVP (5 mg/kg), 4-MEC (100 mg/kg), and METH (3 mg/
kg) no longer decreased but instead produced increased ICSS 
thresholds (although these increases were not significant for 
α-PVP or 4-MEC). Increases in ICSS thresholds have been pos-
tulated to indicate decreases in brain reward function, aversive 
effects, and/or depression-like anhedonia (Vlachou and Markou, 
2011). These higher doses were assessed only once in the cur-
rent study and only in a subset of animals receiving 4-MEC and 
α-PVP because of the appearance of apparent aversive effects 
and thus were not included in statistical analyses. However, 
these observations suggest that high doses of all 3 of these psy-
chostimulants may result in the emergence of deficits in brain 
reward function and/or aversion and anhedonia.
For α-PVP, the observed decreases in ICSS thresholds were 
very similar to those reported here for METH as well as those 
previously reported for MDPV (Watterson et al., 2014). The most 
robust threshold decrease observed for α-PVP was ~19% at the 
1-mg/kg dose, which was similar to the 1 mg/kg dose of METH 
presented here (~20%) and the 0.5-mg/kg dose of MDPV (~18%) 
(Watterson et al., 2012). Both METH and α-PVP resulted in signifi-
cant ICSS threshold reductions at the 0.3- and 1-mg/kg doses. 
However, at the 3-mg/kg dose, METH led to an increase in ICSS 
thresholds (84.39 ± 69.48, mean ± 95% CI), an effect not seen 
until a dose of 5 mg/kg α-PVP was administered (19.83 ± 38.64; 
mean ± 95% CI). Although these effects were not previously 
observed with MDPV doses tested up to 2 mg/kg (Watterson 
et al., 2014), it is likely that higher doses of MDPV would also 
produce elevations in ICSS threshold effects similar to those 
observed in the current study with high doses of α-PVP and 
METH. In addition, the slope of the descending portion of the 
dose-effect curves for α-PVP was most similar to those observed 
after METH (−46.70 vs −50.23), along with the maximal ICSS 
threshold reductions (25.76% vs 21.11%) and ED50 values (0.35 
vs 0.20 mg/kg; see Table 1). Thus, α-PVP and METH are approxi-
mately equipotent in reducing ICSS thresholds; however, when 
compared with our previously published data on MDPV, maxi-
mal ICSS threshold reductions and slopes for both α-PVP and 
METH were approximately one-half those produced by MDPV 
(maximal reduction  =  42.03%, slope  =  −96.07) under identical 
experimental procedures (Watterson et al., 2014). The ED50 dose 
for MDPV was the same α-PVP at 0.35 mg/kg. Again, however, 
this dose was determined by maximal ICSS reductions that 
were approximately twice as robust for MDPV (42.03%) as α-PVP 
(25.76%). Thus, the ability of α-PVP to reduce ICSS thresholds is 
most similar to that of METH but approximately one-half that 
of MDPV.
For 4-MEC, the changes in ICSS thresholds observed in the 
present study closely resemble those previously observed for 
methylone (Watterson et al., 2012), albeit with a rightward shift 
in the dose response curve. The most robust decrease produced 
by 4-MEC was at the 30-mg/kg dose (~15%), similar to the 0.3-
mg/kg doses of α-PVP (~14%) and METH (~13%) in the present 
study, the lowest dose of MDPV (0.1 mg/kg, ~17%) previously 
tested (Watterson et  al., 2014), and most robust, but nonsig-
nificant, methylone dose (10 mg/kg, ~13%) previously reported 
(Watterson et al., 2012). This maximal ICSS threshold decrease is 
also similar to that produced by MDMA (Hubner et al., 1988), but 
significantly less than maximal decreases produced by MDPV 
and METH (Watterson et al., 2014). At the 100-mg/kg dose (only 
assessed in a subset of animals, see Methods), 4-MEC increased 
ICSS thresholds (28.00% ± 31.73; mean ± 95% CI) indicative of 
a biphasic dose-response pattern that is typical of other illicit 
stimulants (Vlachou and Markou, 2011). In addition, neither 
the slope of the descending portion of the dose-effect curve 
for 4-MEC (−21.12) nor the maximal ICSS threshold decrease 
(17.40%) was different from α-PVP or METH. However, the ED50 
value for 4-MEC was significantly different from α-PVP and 
METH, indicating that 4-MEC is less potent than these drugs. 
When compared with our previously published ICSS data for 
methylone (Watterson et al., 2012), 4-MEC led to similar maxi-
mal ICSS threshold reductions (−17.40% vs −21.50%) but much 
higher ED50 values (6.41 vs 1.00) and a slightly steeper slopes 
(−21.12 vs −17.59). However, our previously published study on 
methylone did not assess doses >10 mg/kg; thus, it is possible 
that methylone may have led to greater maximal ICSS threshold 
reductions at higher doses. Although the results from the pre-
sent study suggest that 4-MEC appears to be less potent than 
methylone, yet more effective in reducing ICSS thresholds, fur-
ther experimentation is needed before definitive conclusions 
can be made.
The present study is, to our knowledge, the first to directly 
assess the potential abuse liability of second-generation syn-
thetic cathinones. These results reveal that, like the first-genera-
tion synthetic cathinones now classified as Schedule I controlled 
substances for their high abuse potential, replacement synthetic 
cathinones possess similar rewarding effects as measured in 
ICSS procedures and thus likely possess similar degrees of abuse 
liability in humans. Furthermore, as with first-generation syn-
thetic cathinones, these newer replacement cathinones appear 
to produce rewarding effects similar to the illicit stimulants 
methamphetamine and MDMA (Hubner et al., 1988; Vlachou and 
Markou, 2011). When considering the ICSS data from the present 
study, along with data previously published for MDPV (Watterson 
et al., 2014) and methylone (Watterson et al., 2012) under iden-
tical ICSS experimental conditions, the rank order potency of 
these drugs is MDPV > METH ≈ α-PVP > methylone ≈ 4-MEC.
Synthetic cathinones, like prototypical psychostimulants, 
primarily exert their effects through substrate releasing or 
plasma membrane transporter blocking effects at monoamin-
ergic terminals (Meltzer et al., 2006; Iversen et al., 2013; Lehner 
and Baumann, 2013; Marusich et al., 2014; Simmler et al., 2014). 
As previously mentioned, numerous studies suggest that there 
is a large degree of correspondence between ICSS threshold 
reductions, propensity for drug self-administration, and the 
balance between effects on DA vs 5-HT transmission in the 
mesolimbic reward pathway (Rothman and Baumann, 2003, 
2006; Wee et al., 2005; Bauer et al., 2013a, 2013b). Specifically, 
higher DA/5-HT transporter affinity to release ratios correlate 
with increased self-administration propensity, more robust 
decreases in ICSS thresholds, and greater abuse liability as 
Table 1. Slope Values Represent the Means for the Descending Lin-
ear Slope of Log-Transformed Doses.
Drug Slope ED50 mg/kg Maximal % Reduction 
METH −50.23 0.20: UL = .45, LL = 0.004 −21.11
α-PVP −46.70 0.35: UL = 0.82, LL = 0.023 −25.76
4-MEC −21.12 6.41: UL = 9.23, LL = 4.37 −17.40
MDPV −96.07 0.35: UL = 0.55, LL = 0.17 −42.03
Methylone −17.59 1.00: UL = 1.51, LL = 0.58 −21.50
ED50 values represent the mean dose leading to 50% maximal response with 
upper 95% confidence limits (UL) and lower 95% confidence limits (LL). Maximal 
response values represent the mean maximum intracranial self-stimulation 
(ICSS) threshold reduction (independent of dose) ± 95% confidence intervals. 
Results reported for methylenedioxypyrovalerone (MDPV) and methylone were 
obtained from previous publications (Watterson et al., 2012, 2014).
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indicated by a progressively increased risk for compulsive use. 
Alternatively, lower DA to 5-HT ratios correlate with reduced 
propensity for self-administration, less robust decreases in 
ICSS thresholds, and a lower potential for compulsive drug 
intake. When considering all of the ICSS data from the present 
study along with previously published data on first-generation 
synthetic cathinones (Watterson et al., 2012, 2014) and proto-
typical psychostimulants (Hubner et  al., 1988; Vlachou and 
Markou, 2011), these data generally support a strong positive 
relationship between differential effects on DA/5-HT signaling 
and rewarding effects, as revealed by maximal ICSS thresh-
olds and steepness of slope of the descending portion of dose 
response curve. However, individual comparisons of the in vitro 
DAT/SERT affinities of all of these compounds is not appropri-
ate, since some act primarily as presynaptic plasma membrane 
transporter blockers (MDPV and α-PVP) and others are trans-
porter substrates and monoamine releasers (METH, methyl-
one, and MDMA) or a combination of both (4-MEC). Thus, direct 
comparison of DAT to SERT data (ie, IC50 values) derived from 
inhibition of transporter function as assessed in competitive 
binding assays and data from monoamine release assays (ie, 
EC50 values) is problematic. However, when considering the 
aforementioned rank order potency (MDPV > α-PVP > 4-MEC) 
based on ICSS threshold decreases and slopes of dose response 
curves within the class of monoamine transporter blockers, this 
rank order of potency is in close agreement with DAT to SERT 
ratios derived from IC50 values obtained in previous in vitro 
studies (MDPV [806–816] > α-PVP [806] > 4-MEC [1.85]) (Baumann 
et al., 2012b, 2013; Marusich et al., 2014; Simmler et al., 2014). 
As previously mentioned, 4-MEC is also a weak 5-HT releaser 
(Simmler et al., 2014), which likely further decreases its abuse 
liability. When considering maximal ICSS threshold decreases 
and slopes of the dose response curve for monoamine releas-
ers, their rank order potency is METH > methylone, which cor-
responds with their DAT to SERT ratios derived from EC50 values 
obtain in vitro (METH [152] > methylone [1.82–2]) (Baumann 
et al., 2012a, 2013).
Taken together, we predict that α-PVP possesses a potential 
for compulsive abuse (ie, addiction) that is roughly similar to 
that of METH and MDPV but much greater than that of 4-MEC, 
methylone, and MDMA. Accordingly, we also predict that 4-MEC 
will have a relatively lower potential for compulsive use than 
that of MDPV and METH, would be most similar to methylone 
and MDMA (ie, episodic use), and may exert primarily entacto-
genic effects.
 Finally, it is also important to mention that both first- 
and second-generation synthetic cathinones are often sold 
as mixtures. Specifically, synthetic cathinone products have 
been shown to often contain more than one cathinone, as well 
as other adulterants, including illicit amphetamines, pipera-
zines, cutting/binding agents, caffeine, and topical anesthet-
ics (Brandt et  al., 2010; German et  al., 2014). Thus, although 
abuse liability assessment of these individual drugs is now 
emerging, assessment of the effects and abuse potential of 
combinations of these drugs will be more difficult yet should 
be a central focus of future research. Together, the results of 
the present study suggest that second-generation synthetic 
cathinones likely possess a similar potential for abuse as their 
first-generation predecessors as well as the illicit ampheta-
mines they are designed to mimic. Furthermore, these find-
ings have important implications for future research on 
synthetic cathinone abuse and dependence and legislative 
efforts to classify these drugs according to the proper con-
trolled substance schedule.
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